Published in Lancet Neurol on November 05, 2007
Minocycline to Treat Amyotrophic Lateral Sclerosis | NCT00047723
Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 7.66
The immunology of stroke: from mechanisms to translation. Nat Med (2011) 6.53
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med (2011) 3.16
Amyotrophic lateral sclerosis. Orphanet J Rare Dis (2009) 2.76
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest (2012) 2.67
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology (2011) 2.28
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler (2008) 2.28
Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke (2008) 2.10
A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep (2013) 1.92
Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology (2011) 1.87
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2014) 1.81
Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke (2010) 1.69
Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler (2012) 1.62
Minocycline: far beyond an antibiotic. Br J Pharmacol (2013) 1.59
Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis (2013) 1.58
Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol (2010) 1.52
Progress in periventricular leukomalacia. Arch Neurol (2008) 1.46
Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures. J Neurochem (2008) 1.45
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain (2008) 1.40
Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci (2009) 1.33
The Mitochondrial Permeability Transition Pore: Channel Formation by F-ATP Synthase, Integration in Signal Transduction, and Role in Pathophysiology. Physiol Rev (2015) 1.31
Prospects for minocycline neuroprotection. Arch Neurol (2010) 1.27
Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim Biophys Acta (2009) 1.27
Biology of mitochondria in neurodegenerative diseases. Prog Mol Biol Transl Sci (2012) 1.22
Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull (2013) 1.18
Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther (2013) 1.18
SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome (2011) 1.17
The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J (2013) 1.16
FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J Neurosci (2009) 1.15
Progression in ALS is not linear but is curvilinear. J Neurol (2010) 1.14
Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J Neuroinflammation (2010) 1.13
Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci (2010) 1.12
Pharmacological stabilization of intracranial aneurysms in mice: a feasibility study. Stroke (2012) 1.10
ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J Neurosci (2012) 1.09
Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann Neurol (2009) 1.09
A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One (2012) 1.09
Glial cells in amyotrophic lateral sclerosis. Neurol Res Int (2011) 1.08
Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS. PLoS One (2010) 1.07
Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology (2011) 1.07
Spinal muscular atrophy. Neurotherapeutics (2008) 1.06
The Role of immune and inflammatory mechanisms in ALS. Curr Mol Med (2011) 1.05
The executioners sing a new song: killer caspases activate microglia. Cell Death Differ (2011) 1.02
The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. Front Cell Neurosci (2014) 1.02
Mouse models of Huntington disease: variations on a theme. Dis Model Mech (2009) 1.02
Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 1.00
Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis (2010) 1.00
Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS. PLoS One (2011) 0.99
Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol Sci (2009) 0.99
Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proc Natl Acad Sci U S A (2015) 0.97
Direct protection of cultured neurons from ischemia-like injury by minocycline. Anat Cell Biol (2010) 0.96
Neurovascular matrix metalloproteinases and the blood-brain barrier. Curr Pharm Des (2012) 0.96
ALS drug development: reflections from the past and a way forward. Neurotherapeutics (2008) 0.96
Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1. J Neurovirol (2008) 0.95
Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci (2014) 0.95
Improving outcomes of neuroprotection by minocycline: guides from cell culture and intracerebral hemorrhage in mice. Am J Pathol (2010) 0.94
ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.94
New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig (Lond) (2011) 0.94
A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int (2015) 0.93
Motor neuron-immune interactions: the vicious circle of ALS. J Neural Transm (Vienna) (2010) 0.93
Catalytic antioxidants and neurodegeneration. Antioxid Redox Signal (2009) 0.93
Bioenergetic medicine. Br J Pharmacol (2014) 0.93
Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition. Biochim Biophys Acta (2012) 0.93
Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics (2010) 0.92
Use of minocycline in viral infections. Indian J Med Res (2011) 0.92
A new zebrafish model produced by TILLING of SOD1-related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening. Dis Model Mech (2013) 0.92
Thymic involution, a co-morbidity factor in amyotrophic lateral sclerosis. J Cell Mol Med (2010) 0.91
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology (2012) 0.91
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des (2011) 0.90
Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis. Front Cell Neurosci (2013) 0.90
Spinal but not cortical microglia acquire an atypical phenotype with high VEGF, galectin-3 and osteopontin, and blunted inflammatory responses in ALS rats. Neurobiol Dis (2013) 0.90
Skeletal muscle in motor neuron diseases: therapeutic target and delivery route for potential treatments. Curr Drug Targets (2010) 0.89
Moving forward in clinical trials for ALS: motor neurons lead the way please. Drug Discov Today (2013) 0.89
Experimental models for analysis of oligodendrocyte pathophysiology in stroke. Exp Transl Stroke Med (2009) 0.89
How can we improve clinical trials in amyotrophic lateral sclerosis? Nat Rev Neurol (2011) 0.89
Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention. Adv Pharmacol (2012) 0.89
Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in mice. Brain Res (2009) 0.89
Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem (2010) 0.89
Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals (Basel) (2013) 0.88
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 0.88
Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One (2010) 0.88
Redox modifier genes and pathways in amyotrophic lateral sclerosis. Antioxid Redox Signal (2009) 0.88
Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des (2012) 0.88
Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease. J Neuroimmune Pharmacol (2011) 0.88
Genetic rodent models of amyotrophic lateral sclerosis. J Biomed Biotechnol (2011) 0.87
Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. Mol Neurobiol (2012) 0.86
Inhibition of microglia activation as a phenotypic assay in early drug discovery. J Biomol Screen (2013) 0.86
Biotic acts of antibiotics. Front Microbiol (2013) 0.86
Rodent Models of Amyotrophic Lateral Sclerosis. Curr Protoc Pharmacol (2015) 0.85
Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. J Neurol (2014) 0.85
Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol (2012) 0.85
Delivering minocycline into brain endothelial cells with liposome-based technology. J Cereb Blood Flow Metab (2012) 0.85
Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. Psychopharmacology (Berl) (2010) 0.85
Minocycline inhibits alkali burn-induced corneal neovascularization in mice. PLoS One (2012) 0.84
Bridge between neuroimmunity and traumatic brain injury. Curr Pharm Des (2014) 0.84
Minocycline for patients with ALS. Lancet Neurol (2008) 0.83
Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine (2015) 0.83
Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies. Pharmaceuticals (Basel) (2009) 0.83
Matrix metalloproteinases in neuropathic pain and migraine: friends, enemies, and therapeutic targets. Pain Res Treat (2012) 0.83
Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice. Neurobiol Dis (2008) 0.83
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science (2008) 14.26
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ (2012) 4.23
Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol (2007) 3.96
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum (2013) 3.55
Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med (2007) 3.33
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med (2011) 3.16
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol (2005) 3.07
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A (2013) 2.95
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol (2008) 2.95
Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci (2012) 2.93
Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med (2013) 2.89
The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A (2011) 2.68
Shop for quality or volume? Volume, quality, and outcomes of coronary artery bypass surgery. Ann Intern Med (2009) 2.67
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst (2003) 2.65
Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci (2010) 2.60
Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2012) 2.49
The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve (2013) 2.47
High-dimensional spatial normalization of diffusion tensor images improves the detection of white matter differences: an example study using amyotrophic lateral sclerosis. IEEE Trans Med Imaging (2007) 2.41
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol (2008) 2.41
The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. Plast Reconstr Surg (2012) 2.37
Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med (2007) 2.30
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler (2008) 2.28
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology (2001) 2.27
Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2007) 2.25
Mass media campaigns and organ donation: managing conflicting messages and interests. Med Health Care Philos (2012) 2.19
High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis (2004) 2.13
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology (2012) 2.07
Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst (2010) 2.04
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve (2007) 1.99
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol (2013) 1.91
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol (2013) 1.90
Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res (2010) 1.89
Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat (2009) 1.88
Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis (2005) 1.88
Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res (2002) 1.84
Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. Ann Neurol (2005) 1.83
Effect of hypercarbia and isoflurane on brain cell death and neurocognitive dysfunction in 7-day-old rats. Anesthesiology (2009) 1.82
Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol (2010) 1.81
Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer (2011) 1.77
An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol (2006) 1.73
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.68
The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke (2008) 1.65
Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord (2003) 1.65
LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol (2013) 1.63
Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet (2011) 1.60
Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996. J Am Acad Dermatol (2008) 1.58
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer (2007) 1.57
TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Arch Neurol (2007) 1.57
Scientific, legal, and ethical challenges of end-of-life organ procurement in emergency medicine. Resuscitation (2010) 1.56
Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat (2011) 1.55
Does treatment (nonoperative and operative) improve the two-year quality of life in patients with adult symptomatic lumbar scoliosis: a prospective multicenter evidence-based medicine study. Spine (Phila Pa 1976) (2009) 1.53
Case volume, quality of care, and care efficiency in coronary artery bypass surgery. Arch Intern Med (2010) 1.53
Chronic nerve compression alters Schwann cell myelin architecture in a murine model. Muscle Nerve (2012) 1.53
Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol (2013) 1.52
Primary lateral sclerosis. Muscle Nerve (2007) 1.52
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res (2010) 1.50
The Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: have we put the cart before the horse? Muscle Nerve (2010) 1.49
De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. Hum Mutat (2010) 1.49
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve (2013) 1.48
Modern medicine and the Hippocratic tradition of medicine: restoring professional values. Intensive Care Med (2011) 1.46
Organ procurement after cardiocirculatory death: a critical analysis. J Intensive Care Med (2008) 1.45
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci U S A (2013) 1.44
Hypothetical modeling about the cost effectiveness of kidney transplantation for end-stage renal disease: untested assumptions, unaccounted variables and unknown consequences. Health Policy (2008) 1.43
Experience with the Awaji Island modifications to the ALS diagnostic criteria. Muscle Nerve (2010) 1.43
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat (2010) 1.42
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA (2012) 1.40
Determining brain death after therapeutic hypothermia on nonpulsatile continuous-flow mechanical circulatory support devices. J Cardiothorac Vasc Anesth (2012) 1.39
Islam and end-of-life organ donation. Asking the right questions. Saudi Med J (2009) 1.39
Normative consent and presumed consent for organ donation: a critique. J Med Ethics (2010) 1.39
Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat (2011) 1.39
Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology (2007) 1.38